Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine

Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations

LONDON, June 25, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Verona Pharma’s first-in-class product candidate, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH